Transcranial Magnetic Stimulation for Depression

Overseen By Joan Camprodon, MD, PhD, MPH

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Massachusetts General Hospital

Must be taking: TMS

Disqualifiers: Schizophrenia, Dementia, Substance use, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Approved in 3 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: Unknown

54 Participants Needed

Trial Summary

What is the purpose of this trial?

This is an observational neuroimaging study assessing the effects of TMS on the brains of patients with unipolar depression.

Research Team

Joan Camprodon, MD, MPH, PhD

Principal Investigator

Massachusetts General Hospital

Eligibility Criteria

This trial is for men and women aged 18-80 with a diagnosis of depression who need Transcranial Magnetic Stimulation (TMS) as part of their psychiatric care. It's not suitable for those with MRI contraindications, other primary mental health conditions like schizophrenia, active substance abuse in the past 3 months, or severe medical illnesses.

Inclusion Criteria

I have been diagnosed with depression.

I am between 18 and 80 years old.

I need TMS treatment for my mental health condition.

Exclusion Criteria

Comorbid DSM-IV primary diagnoses of schizoaffective disorder, schizophrenia or dementia

Substance use disorder (abuse or dependence) with active use within the last 3 months

MRI contraindications as determined by MGH department of radiology.

Treatment Details

Interventions

• Transcranial Magnetic Stimulation

Trial Overview The study observes how TMS affects the brain in patients with unipolar depression. This non-invasive treatment uses magnetic fields to stimulate nerve cells in the brain and is being studied using neuroimaging techniques.

Participant Groups

Group I: Unipolar Depression Experimental Treatment 1 Intervention

Patients diagnosed with unipolar depression.

Transcranial Magnetic Stimulation is already approved in United States, Canada, European Union for the following indications:

Approved in United States as Transcranial Magnetic Stimulation for:

• Major Depressive Disorder
• Obsessive Compulsive Disorder

Approved in Canada as Transcranial Magnetic Stimulation for:

• Major Depressive Disorder

Approved in European Union as Transcranial Magnetic Stimulation for:

• Major Depressive Disorder

Who Is Running the Clinical Trial?

Massachusetts General Hospital

Lead Sponsor

Trials

3,066

Recruited

13,430,000+